Referanslar

1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B et al. The EAACI/GA²LEN/EDF/WAo guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414. [Crossref]  [PubMed]
2. Bernstein J, Lang D, Khan D. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1277. [Crossref]  [PubMed]
3. Toubi E, Kessel A, Avshovich N, et al. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy. 2004;59:869e873. [Crossref]  [PubMed]
4. Ito Y, Satoh T, Takayama K, Miyagishi C, Walls AF, Yokozeki H. Basophil recruitment and activation in inflammatory skin diseases. Allergy. 2011; 66:1107- 13. [Crossref]  [PubMed]
5. Kay AB, Clark P, Maurer M, Ying S. Elevations in Thelper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic')urticaria. Br J Dermatol. 2015;172:1294- 302. [Crossref]  [PubMed]
6. Kay AB, Ying S, Ardelean E, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial weals with lowlevel persistence in uninvolved skin. Br J Dermatol. 2014;171:505-11. [Crossref]  [PubMed]  [PMC]
7. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol. 2007;87:196-205. [Crossref]  [PubMed]
8. Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic urticaria: a focus on pathogenesis. F1000Res. 2017;6:1095. [Crossref]  [PubMed]  [PMC]
9. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer o, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139:1772-81. [Crossref]  [PubMed]
10. Chen YJ, Wu CY, Shen JL, Chen TT, Chang YT. Cancer risk in patients with chronic urticaria: a population-based cohort study. Arch Dermatol. 2012;148:103-8. [Crossref]  [PubMed]
11. Kim Z, Choi BS, Kim JK, Won DI. Basophil markers for identification and activation in the indirect basophil activation test by flowcytometry for diagnosis of autoimmune urticaria. Ann Lab Med. 2016;36:28-35. [Crossref]  [PubMed]  [PMC]
12. Gericke J, Metz M, ohanyan T, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol 2017;139: 1059-61. [Crossref]  [PubMed]
13. Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777-80. [Crossref]  [PubMed]
14. Weller KG, Magerl M, Tohme N, et al. Development, validation and initial results of the angioedema activity score. Allergy. 2013;68: 1185-92. [Crossref]  [PubMed]
15. Hawro T, ohanyan T, Schoepke N, et al. Comparison and interpretability of the available urticaria activity scores. Allergy. 2017;73:251-5. [Crossref]  [PubMed]
16. Kuemmerle-Deschner JB, ozen S, Tyrrell PN, et al. Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). Ann Rheum Dis. 2017; 76:942-7. [Crossref]  [PubMed]
17. Marzano AV, Tavecchio S, Venturini M, Sala R, Calzavara-Pinton P, Gattorno M: Urticarial vasculitis and urticarial autoinflammatory syndromes. G Ital Dermatol Venereol 2015;150: 41
18. ortonne JP: Chronic urticaria: a comparison of management guidelines. Expert opin Pharmacother. 2011;12:2683-93. [Crossref]  [PubMed]
19. Akoglu G, Atakan N, Cakir B, Kalayci o, Hayran M. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. Arch Dermatol Res. 2012; 304:257-262. [Crossref]  [PubMed]
20. Kowalski ML, Woessner K, Sanak M. Approaches to the diagnosis and management of patients with a history of nonsteroidal antiinflammatory drug-related urticaria and angioedema. J Allergy Clin Immunol. 2015;136: 245-51. [Crossref]  [PubMed]
21. Schoepke N, Abajian M, Church MK, Magerl M. Validation of a simplified provocation instrument for diagnosis and threshold testing of symptomatic dermographism. Clin Exp Dermatol. 2015;40:399- 403. [Crossref]  [PubMed]
22. Weller K, Ardelean E, Scholz E, Martus P, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, Single-dose study. Acta Derm Venereol 2013;93: 168-74. [Crossref]  [PubMed]
23. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125: 676- 82. [Crossref]  [PubMed]
24. Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992;98: 800-4. [Crossref]  [PubMed]
25. Maurer M, Kaplan A, Ros_en K, et al. The XTENDCIU study: long term use of omalizumab in Chronic Idiopathic Urticaria. J Allergy Clin Immunol 2017.
26. Metz M, ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol 2014;150: 288-90. [Crossref]  [PubMed]
27. Johal KJ, Saini SS. Current and emerging treatments for chronic spontaneous urticaria. Ann Allergy Asthma Immunol. 2019;S1081-1206(19): 31054-3.